GOSS
Gossamer Bio, Inc.
There isn't enough reported data to score GOSS yet.
GOSS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
GOSS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
GOSS PE Valuation
GOSS has no meaningful PE right now: it lost money over the past year.
GOSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GOSS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
GOSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$46.56 | +$7.84 |
| Q2 2026 | -$56.00 | -$7.20 |
| Q1 2026 | -$63.20 | -$45.60 |
| Q4 2025 | -$60.00 | -$40.00 |
| Q3 2025 | -$54.40 | -$45.60 |
| Q2 2025 | -$48.80 | -$34.40 |
| Q1 2025 | -$17.60 | +$50.40 |
| Q4 2024 | -$20.00 | +$74.40 |
GOSS is still losing money, but far less than before: $46.56 per share over the past year, against $284.80 at its worst in mid-2020.
GOSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +189% |
| Q2 2026 | $9.2M | -20% |
| Q1 2026 | $17M | +71% |
| Q4 2025 | $13.8M | +47% |
| Q3 2025 | $13.3M | +40% |
| Q2 2025 | $11.5M | -88% |
GOSS's revenue is recovering but still below its 2024 peak: $38M last quarter, up 189% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +388 points |
| Q2 2026 | -282% | +55 points |
| Q1 2026 | -265% | +108 points |
| Q4 2025 | -334% | +52 points |
| Q3 2025 | -369% | -12 points |
| Q2 2025 | -337% | -392 points |
| Q1 2025 | -372% | N/A |
| Q4 2024 | -385% | N/A |
GOSS's operating margin was 19% last quarter, up 388 points from the same quarter a year ago.
GOSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$29.6M | +$6.6M |
| Q2 2026 | -$39.4M | +$7.7M |
| Q1 2026 | -$38.7M | +$1M |
| Q3 2025 | -$36.2M | -$4.1M |
| Q2 2025 | -$47.1M | -140% |
| Q1 2025 | -$39.8M | +$12.6M |
| Q3 2024 | -$32M | +$2.5M |
| Q2 2024 | $116.3M | +$154.6M |
GOSS has burned cash in almost every quarter: −$156M over the past year, against −$155M the year before.
GOSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +59% | +2.4M shares |
| 1 year | +129% | +3.7M shares |
| 3 years | +447% | +5.3M shares |
| 5 years | +600% | +5.6M shares |
| Available history | +854% | +5.8M shares |
GOSS has 7M diluted shares, up 129% from a year ago.
GOSS Net Leverage
GOSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GOSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 22.1 | Neutral |
GOSS's weekly RSI is 32 (neutral) and its Stochastic is 22 (neutral).
GOSS PE vs Healthcare Sector
GOSS has no meaningful PE right now: it lost money over the past year.
GOSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 11% above |
| 20 week MA | $11.7 | 4% below |
| 50 week MA | $67.1 | 83% below |
| 100 week MA | $100.3 | 89% below |
| 200 week MA | $92.8 | 88% below |
GOSS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 88% below its 200-week average.
GOSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,247.2 | $801.6 | -36% |
| 2021 | $801.6 | $931.2 | +16% |
| 2022 | $931.2 | $152.0 | -84% |
| 2023 | $152.0 | $73.0 | -52% |
| 2024 | $73.0 | $68.4 | -6.3% |
| 2025 | $68.4 | $258.4 | +278% |
| 2026 YTD | $258.4 | $11.2 | -96% |
GOSS's yearly returns have swung widely, from +278% in 2025 to −84% in 2022. It's down 96% so far in 2026.